Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab
Clinical trial NCT04533737 · TERMINATED
Trial details
- NCT number
- NCT04533737
- Sponsor
- LEO Pharma
- Status
- TERMINATED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2020-12-17
- Primary completion
- 2022-09-08
- Enrollment
- 113
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.